Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vaxxas

Vaxxas Expands Global Intellectual Property Portfolio for Exclusive Manufacture and Sale of Needle-Free Vaccination Technology
From Vaxxas
Via Business Wire
Vaxxas Licenses Next-Generation Vaccine for Respiratory Syncytial Virus (RSV) from the United States National Institutes of Health (NIH)
From Vaxxas
Via Business Wire
Vaxxas Initiates Phase I Clinical Trial of Pre-Pandemic Avian Influenza A Virus (H7N9) Vaccine Delivered Using Vaxxas’ Novel High-Density Microarray Patch (HD-MAP)
From Vaxxas
Via Business Wire
Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa
From Vaxxas
Via Business Wire
Vaccine Journal Highlights the Potential for Self-Administration of Vaccines Using Vaxxas High-Density Microarray Patch (HD-MAP)
From Vaxxas
Via Business Wire
Vaxxas Awarded US$3.67 million (AU$5.4 million) from global charitable foundation, Wellcome, for Human Clinical Study of Typhoid Vaccination using Needle-Free Vaccine Patch
From Vaxxas
Via Business Wire
Vaxxas Opens World-Class Manufacturing Facility To Produce Proprietary Needle-Free Vaccine Patch For Late-Stage Clinical Trials and First Commercial Products
From Vaxxas
Via Business Wire
Vaxxas Announces Interim Results from Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using Proprietary High-Density Microarray Patch (HD-MAP)
From Vaxxas
Via Business Wire
Vaxxas Appoints Rochelle Chaiken, M.D., as Chief Medical Officer
From Vaxxas
Via Business Wire
Ease-of-Use and Potential Self-Administration of Vaccination Shown with Vaxxas High Density Microarray Patch (HD-MAP)
From Vaxxas
Via Business Wire
Vaxxas Initiates Phase I Clinical Study of First Needle-Free, Inactivated Seasonal Influenza Vaccine Quadrivalent (IIV4) Delivered Using High-Density Microarray Patch (HD-MAP)
From Vaxxas
Via Business Wire
Coming in From the Cold: Needle-free Patch Technology for Mrna Vaccines Aims to End Need for Frozen Storage and Improve Access
From Vaxxas
Via Business Wire
Vaxxas Raises US$23 million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate
From Vaxxas
Via Business Wire
Vaxxas Appoints Doug Cubbin as Chief Financial Officer
From Vaxxas
Via Business Wire
Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine (HexaPro) Delivered Using High-Density Microarray Patch (HD-MAP)
From Vaxxas
Via Business Wire
Vaxxas receives $8.2 million grant to support manufacturing scale-up in its Australian manufacturing facility
From Vaxxas
Via Business Wire
Vaxxas Announces Appointment of Scott Fry Ph.D. as Chief Operating Officer
From Vaxxas
Via Business Wire
Vaxxas Announces Appointment of Dan Devine as Chief Business Officer and General Counsel
From Vaxxas
Via Business Wire
Vaxxas Licenses HexaPro Spike Glycoprotein from University of Texas at Austin for Use on its Needle-Free Vaccine Patches
From Vaxxas
Via Business Wire
Preclinical Studies From Vaxxas and Collaborators Reveal Potential of Vaxxas’ Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine
From Vaxxas
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.